free counter
World

Novartis drug proven to ease outward indications of painful condition of the skin

Swiss drugmaker Novartis’ logo sometimes appears at the business’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo

Register now free of charge unlimited usage of Reuters.com

FRANKFURT, Sept 10 (Reuters) – Novartis said its anti-inflammatory drug Cosentyx eased the outward symptoms of an agonizing, lump-forming condition of the skin in two late-stage trials, putting the approved treatment on the right track to help expand shore up sales growth at the Swiss drugmaker.

In a statement on Saturday, the business said that the drug, already approved for conditions like psoriasis and arthritis, demonstrated rapid and sustained relief in trial participants experiencing hidradenitis suppurativa.

The business said the painful inflammatory skin condition, that few treatments can be found, affects about 1% of the populace but is difficult to diagnose.

Register now free of charge unlimited usage of Reuters.com

Novartis can be more reliant on drug development since it plans to spin off its generics unit Sandoz, making low-cost copies of treatments which have lost patent protection. read more

Alongside heart failure drug Entresto, Cosentyx is among Novartis’s major revenue growth drivers, with the product’s sales gaining 9% to $1.28 billion through the March-to-June quarter. read more

The Phase III trial results have already been submitted to authorities in Europe and can also be submitted to U.S. regulators this season to get approval for the added indication, Novartis said.

Longer-term follow-up trial data will be published next year, it added.

Register now free of charge unlimited usage of Reuters.com

Reporting by Ludwig Burger; Editing by Christina Fincher

Our Standards: The Thomson Reuters Trust Principles.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker